Judgment of the General Court of 16 June 2021 – Health Product Group v EUIPO – Bioline Pharmaceutical (Enterosgel)
(Case T-678/19) 1
(EU trade mark – Invalidity proceedings – International registration designating the European Union – Figurative mark Enterosgel – No bad faith – Article 51(1)(b) of Regulation (EC) No 40/94 (now Article 59(1)(b) of Regulation (EU) 2017/1001))
Language of the case: English
Parties
Applicant: Health Product Group sp. z o.o. (Warsaw, Poland) (represented by: M. Kondrat, M. Stępień and A. Przytuła, lawyers)
Defendant: European Union Intellectual Property Office (represented by: E. Markakis and V. Ruzek, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Bioline Pharmaceutical AG (Baar, Switzerland) (represented by: T. Grucelski, H. Gajek and M. Furmańska, lawyers)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 8 August 2019 (Case R 482/2018-4), relating to invalidity proceedings between Health Product Group and Bioline Pharmaceutical.
Operative part of the judgment
The Court:
Dismisses the action;
Orders Health Product Group sp. z o.o. to pay the costs.
____________
1 OJ C 399, 25.11.2019.